Etanercept in der Therapie der juvenilen Psoriasis

Abstract

With a prevalence of 0.71%, psoriasis represents one of the most frequent dermatoses in childhood. Eight children with severe psoriasis who failed to respond to other therapy received a weight- adapted treatment with etanercept (0.8mg/kg body) administered subcutaneously once weekly after latent tuberculosis had been excluded. Follow-up visits were at week 4 and 12, subsequently every 12 weeks. Mean age at the start of treatment was 11.8 (range 7-16), six patients were boys. Within three months, six patients reached Psoriasis Area and Severity Index (PASI) reduction of 75%. Two patients stopped use at week 12 because of ineffectiveness. Apart from local side reactions and minor infections, no adverse events were observed. In our case series, etanercept proved to be an efficient drug in juvenile psoriasis without serious adverse events. However, patient registries and further randomized, double-blinded control studies are crucial to evaluate long-term efficacy and safety of etanercept.